Australia markets open in 11 minutes

Bellicum Pharmaceuticals, Inc. (BLCM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.3600-0.0300 (-2.16%)
At close: 03:58PM EST

Bellicum Pharmaceuticals, Inc.

3730 Kirby Drive
Suite 1200
Houston, TX 77098
United States
281 454 3424

Full-time employees7

Key executives

NameTitlePayExercisedYear born
Mr. Richard A. FairPres, CEO & Director915.28kN/A1969
Ms. Charity D. Scripture M.S., Pharm.D.Chief Devel. Officer226.23kN/A1975
Mr. Charles S. GrassPrincipal Accounting OfficerN/AN/A1960
Mr. Joseph SenesacSr. VP of Technical Operations & QualityN/AN/A1970
Dr. Alan K. Smith Ph.D.Chief Scientific OfficerN/AN/A1958
Dr. Aaron E. FosterHead of Research & Sr. VPN/AN/A1973
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

Corporate governance

Bellicum Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.